Clinical Trial

Prognosis of Posterior Lamellar Keratoplasty

Study acronym: CORNEACOHORT
Recruiting
View on ClinicalTrials.gov →
Summary
Over the past decade, the management of Fuchs' endothelial corneal dystrophy (FECD) and pseudophakic bullous keratopathy (PBK) has been revolutionized by the development of posterior lamellar keratoplasty techniques: DSAEK and DMEK. DSAEK (Descemet Stripping Automated Endothelial Keratoplasty) involves replacing the patient's endothelium and pathological descemetum with a descemetic endothelial graft combined with a thin stromal lamella. The endothelial density of the grafts is generally greater than 2,400 cells/mm². Depending on the grafting center and tissue bank, grafts may be either pre-cut in the tissue bank or cut on the operating table by the surgeon himself. The donor graft is placed on an artificial anterior chamber, and automated microkeratome cutting produces grafts with an average thickness of 100 to 200µm, sometimes less than 100um (known as UT-DSAEK or ultra-thin DSAEK). DMEK (Descemet Membrane Endothelial Keratoplasty) is a strictly endothelium and Descemet's membrane graft, as close as possible to the original anatomy of the cornea. The graft is dissected manually either in a tissue bank (pre-cut grafts) or on the operating table by the surgeon. The thickness of the graft is between 15 and 18 microns. The primary objective of this observational cohort is to compare the evolution of visual acuity after DMEK, DSAEK or UT-DSAEK transplantation. Secondary objectives are to compare the evolution of endothelial cell density, corneal thickness and early and late post-operative complications, and to identify factors predictive of these different endpoints.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-28.
Trial Details
NCT Number NCT06859411
Lead Sponsor Centre Hospitalier Régional Metz-Thionville
Conditions Fuchs' Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy
Enrollment 1,000 participants
Start Date 2024-06-01
Primary Completion 2040-01-01 (estimated)
Study Completion 2040-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-24